Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000009374
JPRN-UMIN000009374
Completed
Phase 1

Haploidentical hematopoietic stem cell transplantation in combination with posttransplant cyclophosphamide and ATG-thymoglobulin Phase I study - Post-CY haploHSCT with ATG (MAC)

ational Cancer Center Hospital0 sites15 target enrollmentNovember 21, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionshematological malignancy

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
hematological malignancy
Sponsor
ational Cancer Center Hospital
Enrollment
15
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 21, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •(1\) Organ dysfunction (2\) Uncontrolled hypertension (3\) HIV positive (4\) Uncontrolled active infection (5\) Uncontrolled CNS invasion (6\) Pregnant (7\) Psychiatric disorder (8\) Allergy to drugs used for HSCT (9\) Other reason which physicians think the patient is inappropriate for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide in combination with thymoglobulin (RIC version) Phase IHematological malignancy
JPRN-UMIN000011004ational Cancer Center Hospital12
Completed
Phase 2
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
IRCT138706061030N2Tehran University of Medical Sciences10
Completed
Not Applicable
Allogeneic hematopoietic stem cell transplantation for elderly patients
JPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
Completed
Not Applicable
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)
JPRN-UMIN000026028Osaka City University33
Recruiting
Phase 2
Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II studyAcute leukemia, malignant lymphoma, and solid tumor
JPRN-UMIN000027010Ibaraki Children's Hospital30